Cardiovascular changes associated with venlafaxine in the treatment of late-life depression

American Journal of Geriatric Psychiatry

Volumn 14, Issue 9, 2006, Pages 796-802

  Johnson, Ellyn M ^a   Whyte, Ellen ^a   Mulsant, Benoit H ^a,b,d   Pollock, Bruce G ^a,b   Weber, Elizabeth ^a   Begley, Amy E ^a   Reynolds, Charles F ^a,c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; LORAZEPAM; VENLAFAXINE;

AGED; ANXIETY DISORDER; ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED DRUG RELEASE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DRUG EFFECT; DRUG TOLERABILITY; ECG ABNORMALITY; EXTENDED DRUG RELEASE; FEMALE; HEART PALPITATION; HUMAN; HYPERTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OPEN STUDY; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; QT INTERVAL; QT PROLONGATION; SITTING; STANDING; TACHYCARDIA; TITRIMETRY;

EID: 33748589476     PISSN: 10647481     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.JGP.0000204328.50105.b3     Document Type: Article

References (24)

1. Mulsant BH, Ganguli M: Epidemiology and diagnosis of depression in late life. J Clin Psychiatry 1999; 60 (suppl 20):9-15
2. Charney DS, Reynolds CF III, Lewis L, et al: Depression and Bipolar Support Alliance consensus statement on the unmet needs in diagnosis and treatment of mood disorders in late life. Arch Gen Psychiatry 2003; 60:664-672
3. Mulsant BH, Alexopoulos GS, Reynolds CF, et al: Pharmacological treatment of depression in older primary care patients: the PROSPECT algorithm. Int J Geriatr Psychiatry 2001; 16:585-592
4. Whyte EM, Basinski J, Farhi P, et al: Geriatric depression treatment in nonresponders to selective serotonin reuptake inhibitors. J Clin Psychiatry 2004; 65:1634-1641
5. Mulsant BH, Pollock BG, Nebes R, et al: A 12-week study double-blind, randomized comparison of notriptyline and paroxetine in older depressed inpatients and outpatients. Am J Geriatr Psychiatry 2001; 9:406-414
6. Thase ME, Entsuah R, Cantillon M, et al: Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions. J Women Health 2001; 14:609-616
7. Oslin DW, Ten Have TR, Streim JE, et al: Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents. J Clin Psychiatry 2003; 64:875-882
8. Allard P, Gram L, Timdahl K, et al: Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram. Int J Geriatr Psychiatry 2004; 19:1123-1130
9. Venlafaxine package insert. Wyeth Pharmaceuticals. Philadelphia, PA 1999
10. Kokan L, Dart R: Life-threatening hypotension from venlafaxine overdose. Ann Emerg Med 1996; 27:815
11. Peano C, Leikin JB, Hanashiro PK: Seizures, ventricular tachycardia, and rhabdomyolysis as a result of ingestion of venlafaxine and lamotrigine. Ann Emerg Med 1997; 30:704-708
12. Lessard E, Yessine MA, Hamelin BA, et al: Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics 1999; 9:435-443
13. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62
14. Folstein MF, Folstein SE, McHugh PR: 'Mini-mental state.' A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198
15. Structured Clinical Interview for Axis I DSM-IV Disorders-Patient Edition (SCID-I/P). New York, Biometrics Research Department, NY State Psychiatric Institute, 1995
16. Miller MD, Paradis CF, Houck PR, et al: Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res 1992; 41:237-248
17. Lingjaerde O, Ahlfors UG, Bech P, et al: The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987; 334:1-100
18. Miller MD, Curtiss EI, Marino L, et al: Long-term ECG changes in depressed elderly patients treated with nortriptyline. A double-blind, randomized, placebo-controlled evaluation. Am J Geriatr Psychiatry 1998; 6:59-66
19. Thase ME: Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998; 59:502-508
20. Haddad PM, Anderson IM: Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002; 62: 1649-1671
21. Abdelmawla AH, Langley RW, Szabadi E, et al: Comparison of the effects of venlafaxine, desipramine, and paroxetine on noradrenaline- and methoxamine-evoked constriction of the dorsal hand vein. Br J Clin Pharmacol 1999; 48:345-354
22. Feighner JP: Cardiovascular safety in depressed patients: focus on venlafaxine. J Clin Psychiatry 1995; 56:574-579
23. Harman JS, Mulsant BH, Kelleher KJ, et al: Narrowing the gap in treatment of depression. Int J Psychiatry Med 2001; 31:239-253
24. Whyte E, Romkes M, Mulsant BH, et al: CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly. Intl Geriatr Psychiatry 2006, in press